Drug Profile
Research programme: hydroxysteroid dehydrogenase inhibitors - Merck
Latest Information Update: 29 Aug 2011
Price :
$50
*
At a glance
- Originator Merck & Co
- Class
- Mechanism of Action 11-beta-hydroxysteroid dehydrogenase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Metabolic syndrome
Most Recent Events
- 29 Aug 2011 No development reported - Preclinical for Metabolic syndrome in USA (unspecified route)
- 06 Apr 2006 Preclinical trials in Metabolic syndrome in USA (unspecified route)